Table 4 Clinicopathologic parameters according to the combined immune score (CIS) groups
Variables | Combined immune score (CIS) | |||||
|---|---|---|---|---|---|---|
TCIS | ICIS | |||||
Low (n = 58) | High (n = 169) | P value | Low (n = 60) | High (n = 167) | P value | |
Age (years) | ||||||
< 60 | 55 (94.8%) | 141 (83.4%) | 0.029 | 48 (80.0%) | 148 (88.6%) | 0.095 |
≥ 60 | 3 (5.2%) | 28 (16.6%) |  | 12 (20.0%) | 19 (11.4%) |  |
Tumor size (cm) | ||||||
≤ 2 | 20 (34.5%) | 62 (36.7%) | 0.763 | 15 (25.0%) | 67 (40.1%) | 0.037 |
> 2 | 38 (65.5%) | 107 (63.3%) |  | 45 (75.0%) | 100 (59.9%) |  |
Nuclear score | ||||||
Score 1 & 2 | 20 (34.5%) | 25 (14.8%) | 0.001 | 17 (28.3%) | 28 (16.8%) | 0.054 |
Score 3 | 38 (65.5%) | 144 (85.2%) | Â | 43 (71.7%) | 139 (83.2%) | Â |
Histologic grade | ||||||
Grade 1 & 2 | 18 (31.0%) | 22 (13.0%) | 0.002 | 17 (28.3%) | 23 (13.8%) | 0.011 |
Grade 3 | 40 (69.0%) | 147 (87.0%) | Â | 43 (71.7%) | 144 (86.2%) | Â |
Ductal carcinoma in situ | ||||||
Absent | 13 (22.4%) | 83 (49.1%) |  < 0.001 | 17 (28.3%) | 79 (47.3%) | 0.011 |
Present | 45 (77.6%) | 86 (50.9%) | Â | 43 (71.7%) | 88 (52.7%) | Â |
Lymphovascular invasion | ||||||
Absent | 25 (43.1%) | 110 (65.1%) | 0.003 | 28 (46.7%) | 107 (64.1%) | 0.019 |
Present | 33 (56.9%) | 59 (34.9%) | Â | 32 (53.3%) | 60 (35.9%) | Â |
Lymph node metastasis | ||||||
Absent | 32 (55.2%) | 122 (72.2%) | 0.017 | 40 (66.7%) | 114 (68.3%) | 0.820 |
Present | 26 (44.8%) | 47 (28.8%) | Â | 20 (33.3%) | 53 (31.7%) | Â |
Anatomic stage | ||||||
Stage I & II | 37 (63.8%) | 152 (89.9%) |  < 0.001 | 48 (80.0%) | 141 (84.4%) | 0.430 |
Stage III | 21 (36.2%) | 17 (10.1%) | Â | 12 (20.0%) | 26 (15.6%) | Â |
Prognostic stage | ||||||
Stage I & II | 15 (25.9%) | 47 (27.8%) | 0.774 | 10 (16.7%) | 52 (31.1%) | 0.031 |
Stage III | 43 (74.1%) | 122 (72.2%) | Â | 60 (83.3%) | 115 (68.9%) | Â |